Evaluates Nectin-4 expression for diagnosing urothelial carcinoma in situ, indicating a potential diagnostic advancement.
Nectin-4 has been reported to be frequently overexpressed in urothelial carcinoma; however, its expression and diagnostic utility in urothelial carcinoma in situ (CIS) have not been systematically evaluated. In this study, we compared Nectin-4 expression in 50 cases of urothelial CIS and 50 cases of normal or reactive urothelium. Whole sections were immunohistochemically stained for Nectin-4, CK20 and p53, and staining results were evaluated using the H-score. Membranous Nectin-4 expression was significantly higher in urothelial CIS than in normal or reactive urothelium (p < 0.001) (24/50). A mutation type p53 immunohistochemical pattern was observed in 19/50 CIS cases (38%), while all benign urothelial samples displayed a wild-type pattern. Aberrant CK20 expression was present in 34/50 CIS cases (68%). The combination of CK20 and Nectin-4 detected 74% of CIS cases, exceeding the detection rate obtained with the commonly used CK20/p53 combination (62%) and the Nectin-4/p53 combination (68%). These findings indicate that Nectin-4 is frequently overexpressed in urothelial CIS and may serve as a useful adjunct immunohistochemical marker, particularly in combination with CK20, for the diagnosis of urothelial CIS.
No takes yet. Share an insight, caveat, or question.
Scherping et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: